Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ADGM vs DBVT vs ALKS vs BEAT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ADGM
Adagio Medical Holdings, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$15M
5Y Perf.-81.1%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+249.2%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+23.0%
BEAT
HeartBeam, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-62.1%

ADGM vs DBVT vs ALKS vs BEAT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ADGM logoADGM
DBVT logoDBVT
ALKS logoALKS
BEAT logoBEAT
IndustryMedical - DevicesBiotechnologyBiotechnologyMedical - Healthcare Information Services
Market Cap$15M$1712.35T$5.90B$35M
Revenue (TTM)$-143K$0.00$1.56B$0.00
Net Income (TTM)$-75M$-168M$153M$-21M
Gross Margin-6.2%65.4%
Operating Margin-232.3%12.3%
Forward P/E24.8x
Total Debt$16M$22M$70M$0.00
Cash & Equiv.$21M$194M$1.12B$4M

ADGM vs DBVT vs ALKS vs BEATLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ADGM
DBVT
ALKS
BEAT
StockAug 24May 26Return
Adagio Medical Hold… (ADGM)10018.9-81.1%
DBV Technologies S.… (DBVT)100349.2+249.2%
Alkermes plc (ALKS)100123.0+23.0%
HeartBeam, Inc. (BEAT)10037.9-62.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: ADGM vs DBVT vs ALKS vs BEAT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Adagio Medical Holdings, Inc. is the stronger pick specifically for capital preservation and lower volatility. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ADGM
Adagio Medical Holdings, Inc.
The Defensive Choice

ADGM is the #2 pick in this set and the best alternative if stability is your priority.

  • Beta 0.87 vs DBVT's 1.26
Best for: stability
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +110.4% vs BEAT's -53.7%
Best for: income & stability
ALKS
Alkermes plc
The Growth Play

ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
  • -11.0% 10Y total return vs BEAT's -81.4%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
Best for: growth exposure and long-term compounding
BEAT
HeartBeam, Inc.
The Secondary Option

BEAT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthALKS logoALKS-5.2% revenue growth vs BEAT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs ADGM's -199.9%
Stability / SafetyADGM logoADGMBeta 0.87 vs DBVT's 1.26
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs BEAT's -53.7%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs BEAT's -353.1%

ADGM vs DBVT vs ALKS vs BEAT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ADGMAdagio Medical Holdings, Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
BEATHeartBeam, Inc.
FY 2019
MonitoringCommercial
49.7%$218M
MonitoringMedicare
35.0%$154M
ClinicalTrialSupportandRelatedServices
12.4%$54M
TechnologyDevicesConsumablesandRelatedServices
2.9%$13M

ADGM vs DBVT vs ALKS vs BEAT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGBEAT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

ALKS and ADGM operate at a comparable scale, with $1.6B and -$143,000 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ADGM's -199.9%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
RevenueTrailing 12 months-$143,000$0$1.6B$0
EBITDAEarnings before interest/tax-$67M-$112M$212M-$21M
Net IncomeAfter-tax profit-$75M-$168M$153M-$21M
Free Cash FlowCash after capex-$24M-$151M$392M-$15M
Gross MarginGross profit ÷ Revenue-6.2%+65.4%
Operating MarginEBIT ÷ Revenue-232.3%+12.3%
Net MarginNet income ÷ Revenue-199.9%+9.8%
FCF MarginFCF ÷ Revenue-115.6%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-106.3%+91.5%-4.1%+22.2%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — DBVT and ALKS and BEAT each lead in 1 of 3 comparable metrics.
MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
Market CapShares × price$15M$1712.35T$5.9B$35M
Enterprise ValueMkt cap + debt − cash$10M$1712.35T$4.9B$31M
Trailing P/EPrice ÷ TTM EPS-0.27x-0.76x24.76x-1.40x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.25x
Price / SalesMarket cap ÷ Revenue54.49x4.00x
Price / BookPrice ÷ Book value/share0.73x0.66x3.28x11.27x
Price / FCFMarket cap ÷ FCF12.28x
Evenly matched — DBVT and ALKS and BEAT each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 8 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-8 for ADGM. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADGM's 0.82x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs BEAT's 1/9, reflecting strong financial health.

MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
ROE (TTM)Return on equity-7.5%-130.2%+8.8%-5.7%
ROA (TTM)Return on assets-189.8%-89.0%+5.4%-3.5%
ROICReturn on invested capital+18.9%
ROCEReturn on capital employed-374.1%-145.7%+14.2%-4.6%
Piotroski ScoreFundamental quality 0–94471
Debt / EquityFinancial leverage0.82x0.13x0.04x
Net DebtTotal debt minus cash-$4M-$172M-$1.0B-$4M
Cash & Equiv.Liquid assets$21M$194M$1.1B$4M
Total DebtShort + long-term debt$16M$22M$70M$0
Interest CoverageEBIT ÷ Interest expense-36.69x-189.82x32.30x
ALKS leads this category, winning 7 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $1,053 for ADGM. Over the past 12 months, DBVT leads with a +110.4% total return vs BEAT's -53.7%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ADGM's -52.8% — a key indicator of consistent wealth creation.

MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
YTD ReturnYear-to-date-11.8%+4.9%+25.3%-64.2%
1-Year ReturnPast 12 months-26.1%+110.4%+16.5%-53.7%
3-Year ReturnCumulative with dividends-89.5%+19.7%+14.5%-59.1%
5-Year ReturnCumulative with dividends-89.5%-69.1%+60.9%-81.4%
10-Year ReturnCumulative with dividends-89.5%-87.0%-11.0%-81.4%
CAGR (3Y)Annualised 3-year return-52.8%+6.2%+4.6%-25.8%
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ADGM and ALKS each lead in 1 of 2 comparable metrics.

ADGM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs BEAT's 21.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
Beta (5Y)Sensitivity to S&P 5000.87x1.26x1.00x1.27x
52-Week HighHighest price in past year$2.58$26.18$36.60$4.00
52-Week LowLowest price in past year$0.74$7.53$25.17$0.54
% of 52W HighCurrent price vs 52-week peak+36.9%+76.3%+96.7%+21.8%
RSI (14)Momentum oscillator 0–10037.348.160.237.3
Avg Volume (50D)Average daily shares traded124K252K2.3M1.6M
Evenly matched — ADGM and ALKS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 29.9% for ALKS (target: $46).

MetricADGM logoADGMAdagio Medical Ho…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcBEAT logoBEATHeartBeam, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$46.33$46.00
# AnalystsCovering analysts1528
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

ADGM vs DBVT vs ALKS vs BEAT: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is ADGM or DBVT or ALKS or BEAT a better buy right now?

For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.

2% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ADGM or DBVT or ALKS or BEAT?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -89. 5% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ADGM or DBVT or ALKS or BEAT?

By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.

(ADGM) is the lower-risk stock at 0. 87β versus HeartBeam, Inc. 's 1. 27β — meaning BEAT is approximately 47% more volatile than ADGM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 82% for Adagio Medical Holdings, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ADGM or DBVT or ALKS or BEAT?

By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.

2% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc. grew EPS 27. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ADGM or DBVT or ALKS or BEAT?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ADGM or DBVT or ALKS or BEAT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ADGM or DBVT or ALKS or BEAT better for a retirement portfolio?

For long-horizon retirement investors, Adagio Medical Holdings, Inc.

(ADGM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (ADGM: -89. 2%, BEAT: -81. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ADGM and DBVT and ALKS and BEAT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ADGM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

BEAT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.